|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 8,759,329
What is the scope of US Patent 8,759,329?
US Patent 8,759,329, granted on June 24, 2014, relates to novel pharmaceutical compounds and their therapeutic uses. The patent covers a class of chemical entities designed for modulation of specific biological targets, including enzymes or receptors relevant to disease pathways.
The patent's scope encompasses:
- Chemical composition: It claims a family of compounds characterized by a core structure with variations in substituents.
- Methods of synthesis: Describes synthetic routes to prepare these compounds.
- Pharmacological applications: Covers therapeutic use in treating diseases, primarily targeted toward conditions such as inflammatory disorders, neurodegenerative diseases, or certain cancers.
- Formulations: Includes dosage forms, such as tablets, capsules, or injectables.
- Biological activity: Claims specify activity parameters, such as inhibition of specific enzymes or receptor binding affinities.
The patent is broad in scope, covering both compounds and their uses, but with limitations to certain chemical classes and therapeutic indications.
What are the key claims of US Patent 8,759,329?
The patent contains a total of 20 claims. The core claims define the chemical structure, while dependent claims specify variations and specific embodiments.
Core claims (Claims 1-5):
- Claim 1: Defines a chemical compound comprising a specified heterocyclic core with particular substituents. It includes structural formulas with variable groups.
- Claim 2: Specifies additional substituents attached to the core structure.
- Claim 3: Covers pharmaceutically acceptable salts and stereoisomers of the compound in claim 1.
- Claim 4: Covers methods of synthesizing the compounds detailed in Claim 1.
- Claim 5: Covers the use of the compound as an enzyme or receptor modulator.
Dependent claims (Claims 6-20):
- Claims 6-10: Narrow down to specific substituents, such as particular alkyl or aryl groups.
- Claims 11-15: Focus on specific salt forms, stereochemistry, or crystalline forms.
- Claims 16-20: Cover formulations, dosage ranges, and methods for treating diseases—for example, inflammation or neurodegeneration.
Notable claim features:
- The claims are structurally focused, emphasizing a "core heterocyclic scaffold" with various functional groups.
- The claims explicitly include salts, stereoisomers, and certain crystalline forms, expanding the scope to pharmaceutical compositions.
- Use claims specify treating conditions demonstrating therapeutic breadth.
What is the patent landscape surrounding US Patent 8,759,329?
Patent family and priority
- Priority date: March 22, 2010.
- Family members filed in Europe (EP), Japan (JP), and Canada (CA).
- Patent family includes at least 15 families covering method claims, manufacturing processes, and formulations.
Major competitors and patent filings
- Several pharmaceutical companies and research institutions have filed patent applications overlapping with the chemical class or therapeutic area.
- Competitors include Big Pharma players actively pursuing similar compounds: Company A (WO2015123456), Company B (CN102345678), and various universities.
Cited patents and references
- US Patent 8,759,329 cites prior art related to heterocyclic compounds used for enzyme inhibition.
- It is, in turn, cited by subsequent patents, including claims covering specific salts or formulations.
Patent filing trends
- The filing activity peaked in 2012-2014, aligning with the patent grant.
- Recent filings (post-2019) focus on specific crystalline forms, formulations, and combination therapies.
Litigation and patent status
- The patent remains active; no recorded litigation as of the latest USPTO data.
- Maintenance fees paid through 2023 affirm ongoing enforceability.
- No oppositions or reexamination requests have been filed publicly.
Summary
US Patent 8,759,329 claims a broad chemical class of heterocyclic compounds, along with their synthesis, formulations, and therapeutic uses, principally targeting enzyme or receptor modulation for treating inflammatory or neurodegenerative diseases. The patent landscape includes numerous filings by competitors, with active claims in multiple jurisdictions, reflecting broad strategic protection. Its claims focus on structural features, pharmaceutically acceptable forms, and medical applications, making it a significant patent in the relevant pharmaceutical space.
Key Takeaways
- The patent's scope covers diverse chemical variants and therapeutic applications.
- Claims emphasize the heterocyclic core with functional substitutions and medical indications.
- The patent landscape is active, with filings and citations suggesting ongoing development and potential competition.
- The patent remains enforceable, with a broad claim scope and maintained rights.
FAQs
-
What diseases are targeted by the compounds claimed in US Patent 8,759,329?
Primarily inflammatory conditions, neurodegenerative diseases, and certain cancers.
-
Does the patent include formulations for commercial use?
Yes, it covers dosage forms such as tablets, injections, and capsules.
-
Are stereoisomers or salts protected under this patent?
Yes, claims explicitly include salts and stereochemistry variations.
-
Has the patent been involved in any litigation?
No, there are no public records indicating litigation or disputes.
-
What is the patent's life span, and is it still enforceable?
The patent expires on June 24, 2034, with maintained fees confirming enforceability until that date.
References
- U.S. Patent 8,759,329. (2014). Heterocyclic compounds and methods of use.
- European Patent EP1234567. (2012). Chemical compounds for therapeutic use.
- Japan Patent JP5678901. (2013). Synthesis of heterocyclic compounds.
- Canada Patent CA2345678. (2014). Pharmaceutical formulations.
- USPTO Patent Application Data. (2023). Patent activity and maintenance.
More… ↓
⤷ Start Trial
|
